间充质干细胞治疗移植物抗宿主病的临床研究进展  

Advances of mesenchymal stem cells in treatment of graft-versus-host disease

作　　者：吕梦楠 韩明哲[1] Lyu Mengnan, Han Mingzhe(Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, Chin)

机构地区：[1]中国医学科学院北京协和医学院血液学研究所血液病医院,天津300020

出　　处：《国际输血及血液学杂志》2018年第1期50-54,共5页International Journal of Blood Transfusion and Hematology

摘　　要：移植物抗宿主病（GVHD）的发生、发展显著影响接受异基因造血干细胞移植（allo—HScT）患者的疗效。目前，糖皮质激素联合免疫抑制剂为GVHD的一线治疗方案，但是仍有部分患者治疗效果不佳。因此，探索GVHD更加安全、有效的新治疗方法，成为该领域近年研究的热点。间充质干细胞（MSC）是一类具有自我更新及多向分化能力的非造血干细胞，可对多种免疫细胞进行免疫调节，并在一定条件下发挥免疫抑制作用，故MSC有望成为GVHD的辅助新疗法。笔者拟通过比较MSC治疗GVHD的临床研究，对MSC治疗GVHD的有效性、剂量、给药途径、疗效影响因素，以及并发症等多方面的研究进展进行综述，以期为MSC的应用提供思路。The development of graft-versus-host disease （GVHD） significantly affects the efficacy of allogeneic hematopoietic stern cell transplantation （allo-HSCT）. Glucocorticoid combined with immunosuppressive agents is the first-line treatment of GVHD, but there are still some patients with poor response. Therefore, the treatment of GVHD requires more effective and safer methods. Mesenchymal stem cell （MSC） is a class of non-hematopoietic stem ceils with self renewal and multiple differentiation capacity. They can regulate immune cells and play immunosuppressive effects under certain conditions. MSC will be a new therapy method for GVHD in the future. In order to provide database of MSC application, this review literatures on advances of the effectiveness, dose, route of administration, efficacy factors, complications and other aspects of MSC in treatment of GVHD.

关 键 词：间充质干细胞 移植物抗宿主病 治疗结果 

分 类 号：R457.7[医药卫生—治疗学]